Johnson & Johnson (JNJ)
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
Johnson & Johnson JNJ announced robust second-quarter 2026 results on July 15, beating estimates for both earnings and sales. While earnings rose 4.7%, sales rose 6.6% from the year-ago period.
Why Johnson & Johnson Is a Stock You Can Own Forever
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a stock built to be owned for decades, not traded, because its combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth streak and a diversified healthcare franchise across pharmaceuticals and medical devices is engineered to compound quietly through every market cycle.
3 Dividend Stocks That Have Survived Every Market Crash in July
July tests investor conviction. From the 2011 debt-ceiling standoff to the 2022 inflation shock, summer volatility has separated durable businesses from cyclical hopefuls.
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.
Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.
Is Johnson & Johnson a Buy After Its Latest Earnings Report?
Many traded out of the pharmaceutical sector mainstay to leave it with a nearly 3% loss. While the company posted growth where it counts, the market seems to be expecting notable outperformance from large players in the industry these days.
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Johnson & Johnson's Spravato sales growth supports psychedelic drug opportunity: Jefferies
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression treatment, with Jefferies writing that the drug's commercial performance supports the long-term market opportunity for the sector. Johnson & Johnson (NYSE:JNJ) reported worldwide second-quarter Spravato (esketamine nasal spray) sales of $584 million, up 25% from the first quarter, including US sales of $514 million.
Why Johnson & Johnson's Earnings Dip Looks Like a Buying Opportunity
Johnson & Johnson NYSE: JNJ is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its product portfolio and pipeline, which are producing numerous catalysts simultaneously in 2026.
Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook.
J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue
The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a table-integrated robotic surgical system are among the latest innovations from pharmaceuticals and MedTech company Johnson & Johnson.
